Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H29FN2O4S2 |
| Molecular Weight | 504.637 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C2N=CC(F)=C([C@@H](O)CC[C@@H]3CCN(CCSC4=CC=CS4)C[C@@H]3C(O)=O)C2=C1
InChI
InChIKey=USGHRRVFKSLEJT-WVBUVRCRSA-N
InChI=1S/C25H29FN2O4S2/c1-32-17-5-6-21-18(13-17)24(20(26)14-27-21)22(29)7-4-16-8-9-28(15-19(16)25(30)31)10-12-34-23-3-2-11-33-23/h2-3,5-6,11,13-14,16,19,22,29H,4,7-10,12,15H2,1H3,(H,30,31)/t16-,19+,22+/m1/s1
| Molecular Formula | C25H29FN2O4S2 |
| Molecular Weight | 504.637 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Viquidacin (also known as NXL-101), a quinoline antibacterial agent, was studied as a bacterial DNA gyrase and topoisomerase IV inhibitor. Viquidacin showed potent activity against gram-positive bacteria, including methicillin- and fluoroquinolone-resistant strains. The drug participated in phase I clinical trial. Viquidacin achieved homogeneous and potent bactericidal concentrations in human volunteer plasma. However, further, development was discontinued after QT interval prolongation, which was observed in a healthy volunteer.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:54:30 GMT 2025
by
admin
on
Mon Mar 31 20:54:30 GMT 2025
|
| Record UNII |
0TA0YE45QE
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C258
Created by
admin on Mon Mar 31 20:54:30 GMT 2025 , Edited by admin on Mon Mar 31 20:54:30 GMT 2025
|
||
|
NCI_THESAURUS |
C471
Created by
admin on Mon Mar 31 20:54:30 GMT 2025 , Edited by admin on Mon Mar 31 20:54:30 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C152895
Created by
admin on Mon Mar 31 20:54:30 GMT 2025 , Edited by admin on Mon Mar 31 20:54:30 GMT 2025
|
PRIMARY | |||
|
DTXSID30238172
Created by
admin on Mon Mar 31 20:54:30 GMT 2025 , Edited by admin on Mon Mar 31 20:54:30 GMT 2025
|
PRIMARY | |||
|
300000034459
Created by
admin on Mon Mar 31 20:54:30 GMT 2025 , Edited by admin on Mon Mar 31 20:54:30 GMT 2025
|
PRIMARY | |||
|
11591505
Created by
admin on Mon Mar 31 20:54:30 GMT 2025 , Edited by admin on Mon Mar 31 20:54:30 GMT 2025
|
PRIMARY | |||
|
904302-98-3
Created by
admin on Mon Mar 31 20:54:30 GMT 2025 , Edited by admin on Mon Mar 31 20:54:30 GMT 2025
|
PRIMARY | |||
|
0TA0YE45QE
Created by
admin on Mon Mar 31 20:54:30 GMT 2025 , Edited by admin on Mon Mar 31 20:54:30 GMT 2025
|
PRIMARY | |||
|
8971
Created by
admin on Mon Mar 31 20:54:30 GMT 2025 , Edited by admin on Mon Mar 31 20:54:30 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|